BenzimidazoleCAS# 51-17-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 51-17-2 | SDF | Download SDF |
PubChem ID | 5798 | Appearance | Powder |
Formula | C7H6N2 | M.Wt | 118 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 1H-benzimidazole | ||
SMILES | C1=CC=C2C(=C1)NC=N2 | ||
Standard InChIKey | HYZJCKYKOHLVJF-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C7H6N2/c1-2-4-7-6(3-1)8-5-9-7/h1-5H,(H,8,9) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Benzimidazole Dilution Calculator
Benzimidazole Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 8.4746 mL | 42.3729 mL | 84.7458 mL | 169.4915 mL | 211.8644 mL |
5 mM | 1.6949 mL | 8.4746 mL | 16.9492 mL | 33.8983 mL | 42.3729 mL |
10 mM | 0.8475 mL | 4.2373 mL | 8.4746 mL | 16.9492 mL | 21.1864 mL |
50 mM | 0.1695 mL | 0.8475 mL | 1.6949 mL | 3.3898 mL | 4.2373 mL |
100 mM | 0.0847 mL | 0.4237 mL | 0.8475 mL | 1.6949 mL | 2.1186 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Procaine HCl
Catalog No.:BCC5072
CAS No.:51-05-8
- Pronethalol hydrochloride
Catalog No.:BCC5678
CAS No.:51-02-5
- 7ACC1
Catalog No.:BCC5553
CAS No.:50995-74-9
- 16-Methoxystrychnidin-10-One
Catalog No.:BCN8472
CAS No.:5096-72-0
- N-Methylcoclaurine
Catalog No.:BCN7079
CAS No.:5096-70-8
- Canadine
Catalog No.:BCN5626
CAS No.:5096-57-1
- Crotanecine
Catalog No.:BCN1963
CAS No.:5096-50-4
- Anacrotine
Catalog No.:BCN2057
CAS No.:5096-49-1
- Carminomycin
Catalog No.:BCC6379
CAS No.:50935-04-1, 39472-31-6
- Verminoside
Catalog No.:BCN5625
CAS No.:50932-19-9
- Mizoribine
Catalog No.:BCC4454
CAS No.:50924-49-7
- Bombinakinin M
Catalog No.:BCC5904
CAS No.:509151-65-9
- Fluorouracil (Adrucil)
Catalog No.:BCC2135
CAS No.:51-21-8
- Tiratricol
Catalog No.:BCC4738
CAS No.:51-24-1
- Isoprenaline HCl
Catalog No.:BCC4328
CAS No.:51-30-9
- Scopolamine
Catalog No.:BCN5045
CAS No.:51-34-3
- H-Hyp-OH
Catalog No.:BCC3250
CAS No.:51-35-4
- Norepinephrine
Catalog No.:BCN2206
CAS No.:51-41-2
- Epinephrine Bitartrate
Catalog No.:BCC4348
CAS No.:51-42-3
- Adrenaline
Catalog No.:BCN2191
CAS No.:51-43-4
- Histamine
Catalog No.:BCN2188
CAS No.:51-45-6
- L-Thyroxine
Catalog No.:BCC4917
CAS No.:51-48-9
- Propylthiouracil
Catalog No.:BCC4931
CAS No.:51-52-5
- Atropine
Catalog No.:BCN5639
CAS No.:51-55-8
Structure-Based Design of Novel Benzimidazole Derivatives as Pin1 Inhibitors.[Pubmed:30934730]
Molecules. 2019 Mar 27;24(7). pii: molecules24071198.
Peptidyl-prolyl cis/trans isomerase Pin1 plays a key role in amplifying and translating multiple oncogenic signaling pathways during oncogenesis. The blockade of Pin1 provided a unique way of disrupting multiple oncogenic pathways and inducing apoptosis. Aiming to develop potent Pin1 inhibitors, a series of Benzimidazole derivatives were designed and synthesized. Among the derivatives, compounds 6h and 13g showed the most potent Pin1 inhibitory activity with IC50 values of 0.64 and 0.37 muM, respectively. In vitro antiproliferative assay demonstrated that compounds 6d, 6g, 6h, 6n, 6o and 7c exhibited moderate antiproliferative activity against human prostate cancer PC-3 cells. Taken together, these unique Benzimidazole derivatives exhibited great potential to be further explored as potent Pin1 inhibitors with improved potency.
Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moiety.[Pubmed:30926247]
Bioorg Med Chem Lett. 2019 May 15;29(10):1182-1186.
Previously disclosed Benzimidazole-based DGAT1 inhibitors containing a cyclohexane carboxylic acid moiety suffer from isomerization at the alpha position of the carboxylic acid group, generating active metabolites which exhibit DGAT1 inhibition comparable to the corresponding parent compounds. In this report, we describe the design, synthesis and profiling of Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moiety. Our results show that single isomer 3A maintains in vitro and in vivo inhibition against DGAT1. In contrast to previous lead compounds, 3A does not undergo isomerization during in vitro hepatocyte incubation study or in vivo mouse study.
Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination.[Pubmed:30925337]
Eur J Med Chem. 2019 Mar 14;171:209-220.
The enzyme FabH catalyzes the initial step of fatty acid biosynthesis that is essential for bacterial survival. Therefore, FabH has been identified as an attractive target for the development of new antibacterial agents. We present here the discovery of a promising new series of Pyrazol-Benzimidazole amides with low toxicity and potent FabH inhibitory. Twenty-seven novel compounds have been synthesized, and all the compounds were characterized by (1)H NMR, (13)C NMR and MS. Afterwards they were evaluated for in-vitro antibacterial activities against E. coli, P. aeruginosa, B. subtilis and S. aureus, along with E. coli FabH inhibition and cytotoxicity test. Some compounds proved to be of low toxicity and potent, especially compound 31 exhibited the most potential to be a new drug with MIC of 0.49-0.98mug/mL against the tested bacterial strains and IC50 of 1.22muM against E. coli FabH. Eight analogues 16, 28, 30, 31, 33, 34, 35 and 36 with low range MIC against wild type Xanthomonas Campestris exhibited no inhibition against FabH-deficient mutant strain, which firmly proved the class of compounds arrived at antibacterial activity via interacting with FabH. In silico ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) evaluation also pointed out that these compounds are potential for druggability. Further, effective overall docking scores of all the compounds have been recorded, and docking simulation of compound 31 into E. coli FabH binding pocket has been conducted, where solid binding interactions has been identified.